Allison E. Garda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allison E. Garda has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Amanika Kumar
Mayo Clinic, Department of Obstetrics and Gynecology, Rochester, MN, USA
6 shared publications Michael G. Haddock
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905
5 shared publications- Christopher Leigh Hallemeier
Department of Radiation Oncology, Mayo Clinic, Rochester, MN
4 shared publications - Andrea Giannini
Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
3 shared publications - Carrie Langstraat
Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications - Christopher L. Deufel
Department of Radiation Oncology, Mayo Clinic, Rochester, MN
3 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Advancing Health Equity in Global Oncology: A Collaborative Academic-Cancer Society-Industry Program to Address Health Disparities in Sub-Saharan Africa
PURPOSE: Cancer care capacity in sub-Saharan Africa (SSA) is constrained by late diagnosis and limited treatment access. Few funding mechanisms support innovative, locally led programs to address these challenges. A collaborative initiative was developed to strengthen oncology care through quality improvement (QI) projects. MATERIALS AND METHODS: The program was developed by Global Bridges Oncology (GBO) at Mayo Clinic, Pfizer Global Medical Grants, and the African Organisation for Research and Training in Cancer. A committee composed primarily of African oncology experts guided the process. An RFP was disseminated across SSA in English, French, and Portuguese, inviting applications to improve diagnostic and therapeutic cancer care. Applications underwent a structured, two-stage review, with GBO providing technical support, expert guidance, and training resources. RESULTS: The RFP generated 218 applications reflecting strong demand for oncology QI funding in SSA. After review, 17 projects representing 10 African countries were selected and awarded $1.1 million USD. Funded initiatives reflected four themes: oncology training and clinical practice improvements, early detection and accurate diagnostics, pediatric cancer care, and oncology nursing and palliative medicine. As of March 2026, 11 (65%) of 17 projects are complete, with 4,565 health care professionals engaged through direct training, conference dissemination, system adoption, and sensitization activities, and program-supported services were delivered to more than 47,300 patients. CONCLUSION: This initiative demonstrates the feasibility of a competitive, regionally guided grant program to strengthen cancer care capacity. Early implementation outcomes, including measurable improvements in diagnostic delay, treatment adherence, and care network expansion, confirm that locally led QI initiatives can generate meaningful results across diverse institutional settings. By centering African leadership and supporting diverse QI projects, it advances equitable access to funding, capacity building, and sustainability planning.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Open AccessAdvancing Health Equity in Global Oncology: A Collaborative Academic-Cancer Society-Industry Program to Address Health Disparities in Sub-Saharan Africa
PURPOSE: Cancer care capacity in sub-Saharan Africa (SSA) is constrained by late diagnosis and limited treatment access. Few funding mechanisms support innovative, locally led programs to address these challenges. A collaborative initiative was developed to strengthen oncology care through quality improvement (QI) projects. MATERIALS AND METHODS: The program was developed by Global Bridges Oncology (GBO) at Mayo Clinic, Pfizer Global Medical Grants, and the African Organisation for Research and Training in Cancer. A committee composed primarily of African oncology experts guided the process. An RFP was disseminated across SSA in English, French, and Portuguese, inviting applications to improve diagnostic and therapeutic cancer care. Applications underwent a structured, two-stage review, with GBO providing technical support, expert guidance, and training resources. RESULTS: The RFP generated 218 applications reflecting strong demand for oncology QI funding in SSA. After review, 17 projects representing 10 African countries were selected and awarded $1.1 million USD. Funded initiatives reflected four themes: oncology training and clinical practice improvements, early detection and accurate diagnostics, pediatric cancer care, and oncology nursing and palliative medicine. As of March 2026, 11 (65%) of 17 projects are complete, with 4,565 health care professionals engaged through direct training, conference dissemination, system adoption, and sensitization activities, and program-supported services were delivered to more than 47,300 patients. CONCLUSION: This initiative demonstrates the feasibility of a competitive, regionally guided grant program to strengthen cancer care capacity. Early implementation outcomes, including measurable improvements in diagnostic delay, treatment adherence, and care network expansion, confirm that locally led QI initiatives can generate meaningful results across diverse institutional settings. By centering African leadership and supporting diverse QI projects, it advances equitable access to funding, capacity building, and sustainability planning.
- 14 April 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (4) , 559-568
American Brachytherapy Society Working Group Report on cancer surveillance, sexual health, and pelvic toxicity management in gynecologic malignancies
- 14 April 2026
- Published by Elsevier in Brachytherapy
- Vol. 25 (4) , 559-568
American Brachytherapy Society Working Group Report on cancer surveillance, sexual health, and pelvic toxicity management in gynecologic malignancies
- Open Access
- 18 February 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 58, 101130
Inguinal CTV contouring in anal cancer: comparative validation of inguinal lymph nodes contouring guidelines and implications for consensus
- 18 February 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 58, 101130
Open AccessInguinal CTV contouring in anal cancer: comparative validation of inguinal lymph nodes contouring guidelines and implications for consensus
- 6 June 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 550-563
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion
- 6 June 2025
- Published by Elsevier in Brachytherapy
- Vol. 24 (4) , 550-563
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion
- 31 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (5) , 101805
Multi-center, international endometrial cancer consortium highlights
- 31 March 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (5) , 101805
Multi-center, international endometrial cancer consortium highlights
- 7 February 2025
- Published by Springer Nature in Journal of Cancer Education
- Vol. 40 (5) , 799-803
Mayo Clinic Global Oncology Fellowship: Development and Implementation of a Novel 2-Year Multidisciplinary Training Program for Oncologists from Low- and Middle-Income Countries
Cancer is set to become the leading worldwide cause of premature death and mortality will be disproportionately greater in low-and-middle-income countries (LMIC) due to limitations in physical resources and oncology specialists. To address unmet workforce and educational needs, the Department of Radiation Oncology at Mayo Clinic developed the Global Oncology Fellowship, a 2-year multidisciplinary oncology training program for practicing physicians from LMIC. The fellowship was developed through collaboration with multiple institutional departments and external stakeholders. Eligible fellows are graduates of a recognized international medical school who have completed oncology training in a LMIC and confirm intent to practice in a LMIC. During the 2-year program, fellows rotate through Radiation Oncology, Medical Oncology, Palliative Care, Diagnostic Radiology, radiation dosimetry, research, and leadership development. The program design is flexible and can be tailored to fit the trainee’s clinical needs and interests and focuses on malignancies and technologies that are common in LMIC. The Global Oncology Fellowship was successfully established and supported by benefactor funds. Recruitment of the first trainee faced challenges related to COVID pandemic, completion of medical licensing exams, and obtaining a United States visa. The first fellow started in February 2023 with training ongoing. With the formal approval of the Global Oncology Fellowship in 2024, the program is recruiting for the 2025–2027 academic years. Short- and-long term assessments of the program are ongoing. The Mayo Clinic Global Oncology Fellowship is a multi-disciplinary training program developed to address the educational needs of oncologists in low-and-middle income countries. We hope to contribute to the number of highly trained oncology specialists in LMIC, who will go on to be leaders in clinical care, education, and research.
- 7 February 2025
- Published by Springer Nature in Journal of Cancer Education
- Vol. 40 (5) , 799-803
Mayo Clinic Global Oncology Fellowship: Development and Implementation of a Novel 2-Year Multidisciplinary Training Program for Oncologists from Low- and Middle-Income Countries
Cancer is set to become the leading worldwide cause of premature death and mortality will be disproportionately greater in low-and-middle-income countries (LMIC) due to limitations in physical resources and oncology specialists. To address unmet workforce and educational needs, the Department of Radiation Oncology at Mayo Clinic developed the Global Oncology Fellowship, a 2-year multidisciplinary oncology training program for practicing physicians from LMIC. The fellowship was developed through collaboration with multiple institutional departments and external stakeholders. Eligible fellows are graduates of a recognized international medical school who have completed oncology training in a LMIC and confirm intent to practice in a LMIC. During the 2-year program, fellows rotate through Radiation Oncology, Medical Oncology, Palliative Care, Diagnostic Radiology, radiation dosimetry, research, and leadership development. The program design is flexible and can be tailored to fit the trainee’s clinical needs and interests and focuses on malignancies and technologies that are common in LMIC. The Global Oncology Fellowship was successfully established and supported by benefactor funds. Recruitment of the first trainee faced challenges related to COVID pandemic, completion of medical licensing exams, and obtaining a United States visa. The first fellow started in February 2023 with training ongoing. With the formal approval of the Global Oncology Fellowship in 2024, the program is recruiting for the 2025–2027 academic years. Short- and-long term assessments of the program are ongoing. The Mayo Clinic Global Oncology Fellowship is a multi-disciplinary training program developed to address the educational needs of oncologists in low-and-middle income countries. We hope to contribute to the number of highly trained oncology specialists in LMIC, who will go on to be leaders in clinical care, education, and research.
- Open Access
Intraoperative Radiation Therapy for Recurrent Cervical and Endometrial Cancer: Predicting Morbidity and Mortality in a Contemporary Cohort
Background/Objectives: Our objective was to describe the use of intraoperative radiation therapy (IORT) for the treatment of recurrent/persistent cervical or endometrial cancer and assess predictors of postoperative complications and 3-year mortality. Methods: In this multi-site retrospective study, data were abstracted for recurrent/persistent endometrial or cervical cancer patients who underwent IORT from June 2004 to May 2021. Complications were graded on the six-point Accordion scale. Variables associated with complications were analyzed with univariate logistic regression, while variables associated with death within 3 years were analyzed with Cox proportional hazards modeling. Survival was analyzed with the Kaplan–Meier method. Results: Eighty patients had planned IORT for recurrent/persistent endometrial (n = 35) or cervical cancer (n = 45). The mean age of the cohort was 56.8 years (SD = 13.7), and the median disease-free interval from primary disease to recurrence was 20.0 months (IQR 10.0–63.1). The overall survival at 3 years was 48.6% (95% CI: 38.3–61.6%) with a median survival of 2.8 years. Within 30 days postoperative, 16 patients (20.1%) had grade 3–5 complications and one death (1.3%) occurred. Factors associated with grade 3+ complication included ECOG PS 2–3 (OR 18.00, p = 0.04), neoadjuvant chemotherapy and/or immunotherapy (OR 6.98, p < 0.01), and pelvic sidewall involvement (OR 8.80, p = 0.04). Factors associated with death within 3 years of surgery included ECOG PS 2–3 (HR 8.97, p < 0.01), neoadjuvant chemotherapy and/or immunotherapy (HR 2.34, p = 0.03), whether exenteration was performed (HR 2.64, p = 0.01), and positive resection margin (HR 3.37, p < 0.01). Conclusions: In well-selected patients, IORT is a feasible and safe option for the treatment of recurrent/persistent gynecologic malignancy with an appreciable survival benefit.
Open AccessIntraoperative Radiation Therapy for Recurrent Cervical and Endometrial Cancer: Predicting Morbidity and Mortality in a Contemporary Cohort
Background/Objectives: Our objective was to describe the use of intraoperative radiation therapy (IORT) for the treatment of recurrent/persistent cervical or endometrial cancer and assess predictors of postoperative complications and 3-year mortality. Methods: In this multi-site retrospective study, data were abstracted for recurrent/persistent endometrial or cervical cancer patients who underwent IORT from June 2004 to May 2021. Complications were graded on the six-point Accordion scale. Variables associated with complications were analyzed with univariate logistic regression, while variables associated with death within 3 years were analyzed with Cox proportional hazards modeling. Survival was analyzed with the Kaplan–Meier method. Results: Eighty patients had planned IORT for recurrent/persistent endometrial (n = 35) or cervical cancer (n = 45). The mean age of the cohort was 56.8 years (SD = 13.7), and the median disease-free interval from primary disease to recurrence was 20.0 months (IQR 10.0–63.1). The overall survival at 3 years was 48.6% (95% CI: 38.3–61.6%) with a median survival of 2.8 years. Within 30 days postoperative, 16 patients (20.1%) had grade 3–5 complications and one death (1.3%) occurred. Factors associated with grade 3+ complication included ECOG PS 2–3 (OR 18.00, p = 0.04), neoadjuvant chemotherapy and/or immunotherapy (OR 6.98, p < 0.01), and pelvic sidewall involvement (OR 8.80, p = 0.04). Factors associated with death within 3 years of surgery included ECOG PS 2–3 (HR 8.97, p < 0.01), neoadjuvant chemotherapy and/or immunotherapy (HR 2.34, p = 0.03), whether exenteration was performed (HR 2.64, p = 0.01), and positive resection margin (HR 3.37, p < 0.01). Conclusions: In well-selected patients, IORT is a feasible and safe option for the treatment of recurrent/persistent gynecologic malignancy with an appreciable survival benefit.
- 5 October 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (6) , 676-686
EMVision: An electromagnetic tracking guidance system for accurate placement of interstitial brachytherapy applicators
- 5 October 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (6) , 676-686
EMVision: An electromagnetic tracking guidance system for accurate placement of interstitial brachytherapy applicators